Dolutegravir use is related to lower HTLV-1 proviral load in people co-infected by HIV-1
Abstract Background Infection by human T-cell lymphotropic virus type 1 (HTLV-1) affects millions of people worldwide and causes severe diseases. To date, no specific treatment is available for HTLV infection. The purpose of this study was to determine the impact of Dolutegravir use in reducing HTLV...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Portfolio
2025-12-01
|
| Edice: | Communications Medicine |
| On-line přístup: | https://doi.org/10.1038/s43856-025-01312-9 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|